Curcumin restores innate immune Alzheimer's disease risk gene expression to ameliorate Alzheimer pathogenesis
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) genetics implies a causal role for innate immune genes, TREM2 and CD33, products that oppose each other in the downstream Syk tyrosine kinase pathway, activating microglial phagocytosis of amyloid (Aβ). We report effects of low (Curc-lo) and high (Curc-hi) doses of curcumin on neuroinflammation in APPsw transgenic mice. Results showed that Curc-lo decreased CD33 and increased TREM2 expression (predicted to decrease AD risk) and also increased TyroBP, which controls a neuroinflammatory gene network implicated in AD as well as phagocytosis markers CD68 and Arg1. Curc-lo coordinately restored tightly correlated relationships between these genes’ expression levels, and decreased expression of genes characteristic of toxic pro-inflammatory M1 microglia (CD11b, iNOS, COX-2, IL1β). In contrast, very high dose curcumin did not show these effects, failed to clear amyloid plaques, and dysregulated gene expression relationships. Curc-lo stimulated microglial migration to and phagocytosis of amyloid plaques both in vivo and in ex vivo assays of sections of human AD brain and of mouse brain. Curcumin also reduced levels of miR-155, a micro-RNA reported to drive a neurodegenerative microglial phenotype. In conditions without amyloid (human microglial cells in vitro, aged wild-type mice), Curc-lo similarly decreased CD33 and increased TREM2. Like curcumin, anti-Aβ antibody (also reported to engage the Syk pathway, increase CD68, and decrease amyloid burden in human and mouse brain) increased TREM2 in APPsw mice and decreased amyloid in human AD sections ex vivo. We conclude that curcumin is an immunomodulatory treatment capable of emulating anti-Aβ vaccine in stimulating phagocytic clearance of amyloid by reducing CD33 and increasing TREM2 and TyroBP, while restoring neuroinflammatory networks implicated in neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“V A A uthor M anuscript V A A uthor M anuscript V A A uthor M anuscript predicting reduced Aβ plaques with potential cognitive benefits in a clinical trial (Sevigny et al., 2016).”
BackgroundTREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 2×
“This is consistent with clinical, genetic and basic research, which suggest that aberrant overexpression or increased functional forms of CD33 impede amyloid clearance (Bradshaw et al., 2013; Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013; Malik et al., 2013, 2015; Pottier et al., 2016).”
BackgroundResultKrasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979 · cited 3×
“TREM2 coordinates with microRNA155 in the development of the neurodegenerative activation states, so it is important to assess miR155 when TREM2 is elevated (Krasemann et al., 2017).”
BackgroundVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 2×
“This is consistent with clinical, genetic and basic research, which suggest that aberrant overexpression or increased functional forms of CD33 impede amyloid clearance (Bradshaw et al., 2013; Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013; Malik et al., 2013, 2015; Pottier et al., 2016).”
BackgroundResultYang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · cited 7×
“…show that curcumin has immunomodulatory activity independent of amyloid, we cannot exclude that curcumin bound to amyloid (via the diketone bridge, Yang et al., 2005) also independently alters the inflammatory response; since its metabolite, which binds amyloid with lower infinity, has a reduced…”
BackgroundMethodSelf-citationBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 5×
“, 2008) and Fc-Receptor pathway activation (Bacskai et al., 2001; Bard et al., 2003; Bard et al., 2000), with increased CD68 (Zotova et al.”
BackgroundMethodResultInfluentialInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997 · cited 1×
“Another is to selectively alter innate immune genes linked to increased AD risk, for example, CD33, a sialic acid receptor in microglia (Carrasquillo et al., 2011; Hollingworth et al., 2011; Naj et al., 2011) and Triggering Receptor Expressed on Myeloid cells (TREM2) (Malpass, 2013).”
BackgroundNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901 · cited 1×
“Another is to selectively alter innate immune genes linked to increased AD risk, for example, CD33, a sialic acid receptor in microglia (Carrasquillo et al., 2011; Hollingworth et al., 2011; Naj et al., 2011) and Triggering Receptor Expressed on Myeloid cells (TREM2) (Malpass, 2013).”
BackgroundNeuroinflammation and M2 Microglia: The Good, the Bad, and the Inflamed
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-98 · Cited by 1,748 · cited 1×
“They can also be defined by function, including morphology, phagocytic phenotype, and more complex marker expression (Cherry et al., 2014; Colton and Wilcock, 2010; Colton, 2009; Van Eldik et al., 2016; Weekman et al., 2014).”
BackgroundIntegrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 15×
“NFκB activation, driven by IKK phosphorylation (Zhang et al., 2013) is a direct inhibitory target of curcumin (Bharti et al.”
BackgroundInfluentialMicroglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice
Hickman, S. E., Allison, E. K., & El Khoury, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0616-08.2008 · Cited by 1,329 · cited 2×
“Although initial Aβ aggregates are effectively cleared by innate immune microglia (Lucin et al., 2013; Rogers et al., 2002), clearance fails with chronic inflammation and the onset of amyloid plaques (Hickman et al., 2008; Krabbe et al., 2013).”
BackgroundInflammation in Neurodegenerative Disease—A Double-Edged Sword
Wyss-Coray, T., & Mucke, L. (2002) · Neuron · doi:10.1016/s0896-6273(02)00794-8 · Cited by 1,235 · cited 1×
“Therefore, an alternative immunomodulatory approach to optimize resolution and amyloid clearance could be to coordinate gene expression within the TyroBP network (including increasing TREM2 and decreasing CD33), rather than simply suppressing microglial “activation” (Wyss-Coray and Mucke, 2002) with classic non-steroi…”
BackgroundMicroglia and neuroinflammation: a pathological perspective
Streit (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-14 · Cited by 1,039
Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., Hooli, B., Choi, S. H., Hyman, B. T., & Tanzi, R. E. (2013) · Neuron · doi:10.1016/j.neuron.2013.04.014 · Cited by 1,004
TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151948 · Cited by 840 · cited 1×
“, 2011) to plaques that can depend on TREM2 (Cheng-Hathaway et al., 2018; Wang et al., 2016), and stimulates amyloid clearance tracked by multiphoton imaging (Garcia-Alloza et al.”
BackgroundYuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.003 · Cited by 817
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis
Kleinberger, G., Yamanishi, Y., Suárez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., Struyfs, H., Pettkus, N., Wenninger-Weinzierl, A., Mazaheri, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009093 · Cited by 798 · cited 2×
“TREM2 AD-risk SNPs greatly reduce cellular phagocytic activity (Kleinberger et al., 2014).”
BackgroundDystrophic microglia in the aging human brain
Streit, W. J., Sammons, N. W., Kuhns, A. J., & Sparks, D. L. (2004) · Glia · doi:10.1002/glia.10319 · Cited by 705
Jay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142322 · Cited by 682 · cited 1×
“, 2010), which may occur in invading macrophages (Jay et al., 2015) or resident microglia (Hickman and El Khoury, 2014; Wang et al.”
BackgroundBegum, A. N., Jones, M. R., Lim, G. P., Morihara, T., Kim, P., Heath, D. D., Rock, C. L., Pruitt, M. A., Yang, F., Hudspeth, B., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137455 · Cited by 604 · cited 4×
“, 2005) also independently alters the inflammatory response; since its metabolite, which binds amyloid with lower infinity, has a reduced effect on clearance of amyloid (Begum et al., 2008).”
BackgroundSelf-citationCD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
Initiative, T. A. D. N., Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L. L., Imboywa, S., Lee, M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3435 · Cited by 570 · cited 2×
“This is consistent with clinical, genetic and basic research, which suggest that aberrant overexpression or increased functional forms of CD33 impede amyloid clearance (Bradshaw et al., 2013; Griciuc et al., 2013; Guerreiro et al., 2013; Jonsson et al., 2013; Malik et al., 2013, 2015; Pottier et al., 2016).”
BackgroundResultLate onset Alzheimer’s disease genetics implicates microglial pathways in disease risk
Efthymiou, A. G., & Goate, A. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0184-x · Cited by 562
Protective effects of NSAIDs on the development of Alzheimer disease
Vlad, S. C., Miller, D. R., Kowall, N. W., & Felson, D. T. (2008) · Neurology · doi:10.1212/01.wnl.0000311269.57716.63 · Cited by 535 · cited 1×
“, 2003), clinical data have yielded mixed results (Aisen, 2008; Breitner et al., 2011; Pasqualetti et al., 2009; Sonnen et al., 2010; Vlad et al., 2008).”
ResultPhenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology
Frautschy, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00300-1 · Cited by 514
Self-citationKrabbe, G., Halle, A., Matyash, V., Rinnenthal, J. L., Eom, G. D., Bernhardt, U., Miller, K. R., Prokop, S., Kettenmann, H., & Heppner, F. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060921 · Cited by 478 · cited 2×
“, 2002), clearance fails with chronic inflammation and the onset of amyloid plaques (Hickman et al., 2008; Krabbe et al., 2013).”
BackgroundKoenigsknecht-Talboo, J., & Landreth, G. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1808-05.2005 · Cited by 477 · cited 1×
“Aβ aggregates in vitro (Michelucci et al., 2009) and in vivo (Hickman et al., 2008) polarize microglia toward M1 and away from M2 phenotype, which decreases Aβ clearance (Koenigsknecht-Talboo and Landreth, 2005).”
BackgroundKitazawa, M., Cheng, D., Tsukamoto, M. R., Koike, M. A., Wes, P. D., Vasilevko, V., Cribbs, D. H., & LaFerla, F. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100620 · Cited by 473 · cited 1×
“…while increasing Arg1 and other M2 microglial markers (Jiang et al., 2016) while TREM2 SNPs impact CSF tau, tangles, and AD progression (Cruchaga et al., 2013) arguing for a positive TREM2 role beyond amyloid phagocytosis (Ghosh et al., 2013; Kitazawa et al., 2011; Li et al., 2003).”
BackgroundDisease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of Alzheimer's Disease
Jay, T. R., Hirsch, A. M., Broihier, M. L., Miller, C. M., Neilson, L. E., Ransohoff, R. M., Lamb, B. T., & Landreth, G. E. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2110-16.2016 · Cited by 457
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
DeMattos, R. B., Lu, J., Tang, Y., Racke, M. M., DeLong, C. A., Tzaferis, J. A., Hole, J. T., Forster, B. M., McDonnell, P. C., Liu, F., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.10.029 · Cited by 442 · cited 4×
“Active or passive anti-Aβ antibodies also act to increase amyloid phagocytosis (Bard et al., 2000; Demattos et al., 2012; Ostrowitzki et al., 2012; Schenk et al., 1999) via microglial recruitment (Koenigsknecht-Talboo et al., 2008) and Fc-Receptor pathway activation (Bacskai et al., 2001; Bard et…”
BackgroundMethodResultInfluentialTREM2, microglia, and neurodegenerative diseases
Yeh, F. L., Hansen, D. V., & Sheng, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.008 · Cited by 440 · cited 1×
“TREM2 is a classical innate immune system receptor restricted to microglia in the brain (Ulrich et al., 2017; Yeh et al., 2017) (and related peripheral cells) that requires interaction with TyroBP for its signaling through tyrosine kinases.”
BackgroundTMEM119 marks a subset of microglia in the human brain
Satoh, J., Kino, Y., Asahina, N., Takitani, M., Miyoshi, J., Ishida, T., & Saito, Y. (2016) · Neuropathology · doi:10.1111/neup.12235 · Cited by 434
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431
Takahashi, K., Prinz, M., Stagi, M., Chechneva, O., & Neumann, H. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040124 · Cited by 414 · cited 1×
“, 2012), promoting pro-phagocytic and anti-inflammatory activities (Painter et al., 2015; Takahashi et al., 2007) in amyloid plaque-associated microglia (Frank et al.”
BackgroundBard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., Guido, T., Hoenow, K., Hu, K., Johnson-Wood, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436286100 · Cited by 411
Michelucci, A., Heurtaux, T., Grandbarbe, L., Morga, E., & Heuschling, P. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.02.003 · Cited by 411
Ghosh, S., Wu, M. D., Shaftel, S. S., Kyrkanides, S., LaFerla, F. M., Olschowka, J. A., & O'Banion, M. K. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4361-12.2013 · Cited by 390
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B. A., Jeng, A. T., Skorupa, T., Carrell, D., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.026 · Cited by 383 · cited 1×
“, 2016) while TREM2 SNPs impact CSF tau, tangles, and AD progression (Cruchaga et al., 2013) arguing for a positive TREM2 role beyond amyloid phagocytosis (Ghosh et al.”
BackgroundMicroglia and inflammatory mechanisms in the clearance of amyloid β peptide
Rogers, J., Strohmeyer, R., Kovelowski, C. J., & Li, R. (2002) · Glia · doi:10.1002/glia.10153 · Cited by 381
Lucin, K. M., O’Brien, C. E., Bieri, G., Czirr, E., Mosher, K. I., Abbey, R. J., Mastroeni, D. F., Rogers, J., Spencer, B., Masliah, E., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.046 · Cited by 374
Cox, K. H., Pipingas, A., & Scholey, A. B. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114552744 · Cited by 368
Mandrekar-Colucci, S., Karlo, J. C., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5268-11.2012 · Cited by 355 · cited 1×
“One approach to identifying a therapeutic target is to increase expression of selected M2related microglial genes (Mandrekar-Colucci et al., 2012).”
BackgroundCan Alzheimer disease be prevented by amyloid-β immunotherapy?
Lemere, C. A., & Masliah, E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.219 · Cited by 351 · cited 1×
“Clearance of Aβ with antibody (Lemere and Masliah, 2010) requires TREM2 expression (Xiang et al.”
BackgroundElucidating the Role of TREM2 in Alzheimer’s Disease
Ulrich, J. D., Ulland, T. K., Colonna, M., & Holtzman, D. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.042 · Cited by 325
Apo E structure determines VLDL clearance and atherosclerosis risk in mice
Knouff, C., Hinsdale, M. E., Mezdour, H., Altenburg, M. K., Watanabe, M., Quarfordt, S. H., Sullivan, P. M., & Maeda, N. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6172 · Cited by 324
Jiang, T., Tan, L., Zhu, X.-C., Zhang, Q.-Q., Cao, L., Tan, M.-S., Gu, L.-Z., Wang, H.-F., Ding, Z.-Z., Zhang, Y.-D., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.164 · Cited by 320 · cited 1×
“Regardless, lentiviral-directed microglial overexpression of TREM2 decreased amyloid, neurodegeneration, and neuroinflammation in young (Jiang et al., 2014) but not old mice (Jiang et al., 2017).”
BackgroundAltered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2
Ulrich, J. D., Finn, M. B., Wang, Y., Shen, A., Mahan, T. E., Jiang, H., Stewart, F. R., Piccio, L., Colonna, M., & Holtzman, D. M. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-20 · Cited by 302 · cited 1×
“For example, 50% TREM2 loss altered microglial morphology but had little effect on plaques (Ulrich et al., 2014) or increased plaques (Cheng-Hathaway et al.”
BackgroundSong, W., Hooli, B., Mullin, K., Jin, S. C., Cella, M., Ulland, T. K., Wang, Y., Tanzi, R. E., & Colonna, M. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.004 · Cited by 297
ApoE facilitates the microglial response to amyloid plaque pathology
Ulrich, J. D., Ulland, T. K., Mahan, T. E., Nyström, S., Nilsson, K. P., Song, W. M., Zhou, Y., Reinartz, M., Choi, S., Jiang, H., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171265 · Cited by 297 · cited 1×
“TREM2-ir plaque-associated microglia in APP/PS1 are reduced with ApoE deletion (Ulrich et al., 2018).”
BackgroundFrackowiak, J., Wisniewski, H. M., Wegiel, J., Merz, G. S., Iqbal, K., & Wang, K. C. (1992) · Acta Neuropathologica · doi:10.1007/bf00227813 · Cited by 276
Evidence That Aging And Amyloid Promote Microglial Cell Senescence
Flanary, B. E., Sammons, N. W., Nguyen, C., Walker, D., & Streit, W. J. (2007) · Rejuvenation Research · doi:10.1089/rej.2006.9096 · Cited by 272 · cited 1×
“Aging (Flanary et al., 2007) without amyloid drives microglial gene expression changes that include significant reductions in TREM2, and in TyroBP (DAP12), central to a microglial “sensome” hub (Hickman et al.”
BackgroundAPOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease
Youmans, K. L., Tai, L. M., Nwabuisi-Heath, E., Jungbauer, L., Kanekiyo, T., Gan, M., Kim, J., Eimer, W. A., Estus, S., Rebeck, G. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.407957 · Cited by 268 · cited 1×
“…mice (n = 5) (human ApoE3 allele targeted replacement (Knouff et al., 1999), either transgenic for 5 FAD mutations in the human APP and PS1 genes (Youmans et al., 2012) (Tg+), or littermates without the 5xFAD transgenes (Tg-)), that were treated for 2 months with 500 ppm curcumin in diet…”
MethodThe Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease
Cheng-Hathaway, P. J., Reed-Geaghan, E. G., Jay, T. R., Casali, B. T., Bemiller, S. M., Puntambekar, S. S., von Saucken, V. E., Williams, R. Y., Karlo, J. C., Moutinho, M., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0262-8 · Cited by 252 · cited 3×
“, 2011) to plaques that can depend on TREM2 (Cheng-Hathaway et al., 2018; Wang et al., 2016), and stimulates amyloid clearance tracked by multiphoton imaging (Garcia-Alloza et al.”
BackgroundTREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice
Frank, S., Burbach, G. J., Bonin, M., Walter, M., Streit, W., Bechmann, I., & Deller, T. (2008) · Glia · doi:10.1002/glia.20710 · Cited by 247 · cited 1×
“TREM2 is focally upregulated along with TyroBP/DAP12 in phagocytic microglia-like cells around plaques (Frank et al., 2008; Melchior et al., 2010), which may occur in invading macrophages (Jay et al.”
BackgroundTREM2 and the neuroimmunology of Alzheimer's disease
Hickman, S. E., & El Khoury, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.021 · Cited by 221
Chung, H., Brazil, M. I., Soe, T. T., & Maxfield, F. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32301 · Cited by 212
Kamphuis, W., Kooijman, L., Schetters, S., Orre, M., & Hol, E. M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.07.007 · Cited by 209
TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance
Xiang, X., Werner, G., Bohrmann, B., Liesz, A., Mazaheri, F., Capell, A., Feederle, R., Knuesel, I., Kleinberger, G., & Haass, C. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606370 · Cited by 183 · cited 2×
“Clearance of Aβ with antibody (Lemere and Masliah, 2010) requires TREM2 expression (Xiang et al., 2016).”
Insights into TREM2 biology by network analysis of human brain gene expression data
Forabosco, P., Ramasamy, A., Trabzuni, D., Walker, R., Smith, C., Bras, J., Levine, A. P., Hardy, J., Pocock, J. M., Guerreiro, R., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.001 · Cited by 180 · cited 1×
“Our data provide a plausible role for increasing coordinated TREM2/ TyroBP hub gene expression controlling many genes involved in microglial motility, migration and phagocytosis (Forabosco et al., 2013).”
BackgroundTREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice
Jiang, T., Zhang, Y.-D., Chen, Q., Gao, Q., Zhu, X.-C., Zhou, J.-S., Shi, J.-Q., Lu, H., Tan, L., & Yu, J.-T. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.028 · Cited by 176 · cited 1×
“Nevertheless TREM2 overexpression in tau-p301s mice also limited tauopathy, neurodegeneration, and neuroinflammation, while increasing Arg1 and other M2 microglial markers (Jiang et al., 2016) while TREM2 SNPs impact CSF tau, tangles, and AD progression (Cruchaga et al.”
BackgroundPasqualetti, P., Bonomini, C., Dal Forno, G., Paulon, L., Sinforiani, E., Marra, C., Zanetti, O., & Maria Rossini, P. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03325217 · Cited by 172
TREM2 in CNS homeostasis and neurodegenerative disease
Painter, M. M., Atagi, Y., Liu, C.-C., Rademakers, R., Xu, H., Fryer, J. D., & Bu, G. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0040-9 · Cited by 169
Genetics ignite focus on microglial inflammation in Alzheimer’s disease
Malik, M., Parikh, I., Vasquez, J. B., Smith, C., Tai, L., Bu, G., LaDu, M. J., Fardo, D. W., Rebeck, G. W., & Estus, S. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0048-1 · Cited by 161 · cited 1×
“This signaling is opposed by CD33linked tyrosine phosphatases (Malik et al., 2015) (Fig.”
BackgroundArginase 1+ microglia reduce Aβ plaque deposition during IL-1β-dependent neuroinflammation
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0411-8 · Cited by 152
Koenigsknecht-Talboo, J., Meyer-Luehmann, M., Parsadanian, M., Garcia-Alloza, M., Finn, M. B., Hyman, B. T., Bacskai, B. J., & Holtzman, D. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4147-08.2008 · Cited by 149 · cited 1×
“…increase amyloid phagocytosis (Bard et al., 2000; Demattos et al., 2012; Ostrowitzki et al., 2012; Schenk et al., 1999) via microglial recruitment (Koenigsknecht-Talboo et al., 2008) and Fc-Receptor pathway activation (Bacskai et al., 2001; Bard et al., 2003; Bard et al., 2000), with increased…”
BackgroundMa, Q., Lim, G. P., Harris‐White, M. E., Yang, F., Ambegaokar, S. S., Ubeda, O. J., Glabe, C. G., Teter, B., Frautschy, S. A., & Cole, G. M. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20734 · Cited by 126 · cited 1×
“We have previously shown 10G4 antibody treatment reduces amyloid in Tg2576 mice (Ma et al., 2006, 2007).”
BackgroundSelf-citationTYROBP genetic variants in early-onset Alzheimer's disease
Pottier, C., Ravenscroft, T. A., Brown, P. H., Finch, N. A., Baker, M., Parsons, M., Asmann, Y. W., Ren, Y., Christopher, E., Levitch, D., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.07.028 · Cited by 94
Fisher, Y., Nemirovsky, A., Baron, R., & Monsonego, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010830 · Cited by 83 · cited 1×
“Vaccination with Aβ in AD model mice increases TREM2 and amyloid clearance (Fisher et al., 2010), while TREM2 deficiency decreases anti-Aβ-induced amyloid clearance (Xiang et al.”
BackgroundIbuprofen modifies cognitive disease progression in an Alzheimer’s mouse model
Van Dam, D., Coen, K., & De Deyn, P. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108097630 · Cited by 45
Cited by
Agu, P. C., Afiukwa, C. A., Orji, O. U., Ezeh, E. M., Ofoke, I. H., Ogbu, C. O., Ugwuja, E. I., & Aja, P. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-40160-2 · Cited by 1,211
Inflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review
Twarowski, B., & Herbet, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076518 · Cited by 412
Memarzia, A., Khazdair, M. R., Behrouz, S., Gholamnezhad, Z., Jafarnezhad, M., Saadat, S., & Boskabady, M. H. (2021) · BioFactors · doi:10.1002/biof.1716 · Cited by 254
MiR-155: An Important Regulator of Neuroinflammation
Zingale, V. D., Gugliandolo, A., & Mazzon, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010090 · Cited by 163
CD47 in the Brain and Neurodegeneration: An Update on the Role in Neuroinflammatory Pathways
Gheibihayat, S. M., Cabezas, R., Nikiforov, N. G., Jamialahmadi, T., Johnston, T. P., & Sahebkar, A. (2021) · Molecules · doi:10.3390/molecules26133943 · Cited by 34
Metadata
- Authors
- Teter, B., Morihara, T., Lim, G. P., Chu, T., Jones, M. R., Zuo, X., Paul, R. M., Frautschy, S. A., & Cole, G. M.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2019-07
- Volume
- 127
- Pages
- 432-448
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2934961672
- Cited by
- 124
- References
- 72
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.